Correspondence 0000950170-23-012568 from ASSEMBLY BIOSCIENCES, INC. (ASMB)
ASSEMBLY BIOSCIENCES, INC.
Date: April 12, 2023 · CIK: 0001426800 · Accession: 0000950170-23-012568
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-270760
Letter
Re: Assembly Biosciences, Inc.
April 12, 2023
Via EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Registration Statement on Form S-3
Filed March 22, 2023
File No. 333-270760
Request for Acceleration of Effective Date
Ladies and Gentlemen:
Pursuant to Rule 461 of the Securities Act of 1933, as amended, Assembly Biosciences, Inc. (the “Company”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-270760) (the “Registration Statement”) to 4:30 p.m. Eastern Time on Friday, April 14, 2023 or as soon thereafter as practicable.
The Company acknowledges that both the Company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff of the U.S. Securities and Exchange Commission.
Please contact P. Michelle Gasaway of Skadden, Arps, Slate, Meagher & Flom LLP, special counsel to the Company, at +1.213.687.5122 as soon as the Registration Statement has been declared effective or if you have any other questions or concerns regarding this matter.
Regards,
By: /s/ Jason A. Okazaki
Show Raw Text
CORRESP 1 filename1.htm CORRESP April 12, 2023 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Assembly Biosciences, Inc. Registration Statement on Form S-3 Filed March 22, 2023 File No. 333-270760 Request for Acceleration of Effective Date Ladies and Gentlemen: Pursuant to Rule 461 of the Securities Act of 1933, as amended, Assembly Biosciences, Inc. (the “Company”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-270760) (the “Registration Statement”) to 4:30 p.m. Eastern Time on Friday, April 14, 2023 or as soon thereafter as practicable. The Company acknowledges that both the Company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff of the U.S. Securities and Exchange Commission. Please contact P. Michelle Gasaway of Skadden, Arps, Slate, Meagher & Flom LLP, special counsel to the Company, at +1.213.687.5122 as soon as the Registration Statement has been declared effective or if you have any other questions or concerns regarding this matter. Regards, By: /s/ Jason A. Okazaki Name: Jason A. Okazaki Title: Chief Executive Officer and President cc: P. Michelle Gasaway Skadden, Arps, Slate, Meagher & Flom LLP John O. Gunderson Assembly Biosciences, Inc. 331 Oyster Point Blvd., 4th Flr., South San Francisco, CA 94080